{
    "clinical_study": {
        "@rank": "114212", 
        "arm_group": [
            {
                "arm_group_label": "patients  with and without treatment by L dopa)", 
                "arm_group_type": "Experimental", 
                "description": "to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money."
            }, 
            {
                "arm_group_label": "healthy paired control", 
                "arm_group_type": "Other", 
                "description": "to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control."
            }
        ], 
        "brief_summary": {
            "textblock": "Use lay language.\n\n      Many decisions involve the possibility of gaining or losing relative to the status quo. The\n      loss aversion behaviour is a cognitive concept explaining that people are more sensitive to\n      the possibility of losing objects or money than they are to the possibility of gaining the\n      same objects or amounts of money.\n\n      We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight\n      this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary\n      purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by\n      comparing brain activity in parkinsonian patient with and without treatment with L Dopa,\n      when they are exposed to mixed (gain/loss) gambles using money.\n\n      The second purpose is to highlight the role of a dopamine depletion by comparing patient\n      without treatment vs healthy paired control.\n\n      2 groups :\n\n        -  20 parkinsonian patients (tested two times : with and without treatment by L dopa)\n\n        -  20 healthy paired control\n\n      Description of the protocol for patients :\n\n      J0 : Inclusion visit (duration : 4h):\n\n        -  motor assessment (UPDRS)\n\n        -  neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin\n           scale, UPPS, MADRS, Hamilton, LARS).\n\n      J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or\n      without treatment) :\n\n      Each acquisition was composed by an orientation sequence+ an anatomic sequence + a\n      functional sequence.\n\n      For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the\n      MRI acquisitions."
        }, 
        "brief_title": "Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Use lay language.\n\n      Many decisions involve the possibility of gaining or losing relative to the status quo. The\n      loss aversion behaviour is a cognitive concept explaining that people are more sensitive to\n      the possibility of losing objects or money than they are to the possibility of gaining the\n      same objects or amounts of money.\n\n      We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight\n      this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary\n      purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by\n      comparing brain activity in parkinsonian patient with and without treatment with L Dopa,\n      when they are exposed to mixed (gain/loss) gambles using money.\n\n      The second purpose is to highlight the role of a dopamine depletion by comparing patient\n      without treatment vs healthy paired control.\n\n      2 groups :\n\n        -  20 parkinsonian patients (tested two times : with and without treatment by L dopa)\n\n        -  20 healthy paired control\n\n      Description of the protocol for patients :\n\n      J0 : Inclusion visit (duration : 4h):\n\n        -  motor assessment (UPDRS)\n\n        -  neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin\n           scale, UPPS, MADRS, Hamilton, LARS).\n\n      J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or\n      without treatment) :\n\n      Each acquisition was composed by an orientation sequence+ an anatomic sequence + a\n      functional sequence.\n\n      For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the\n      MRI acquisitions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients :\n\n          -  Men or women aged between 35 -75 years\n\n          -  Patients with an idiopathic Parkinson's disease according to UKPDSBB criterias with a\n             disease evolution duration : 5-10 years)\n\n          -  With fluctuations in end of doses + morning akinesia.\n\n          -  Non dement (MMS>24 ; Mattis > 130)\n\n          -  Affiliated to National Health system\n\n          -  Having given their informed consent\n\n        Healthy controls\n\n          -  Men or women aged between 35 to 75 years\n\n          -  Non dement (MMS>24 )\n\n          -  Affiliated to National Health system\n\n          -  Having given their informed consent\n\n        Exclusion Criteria:\n\n          -  Patients :\n\n          -  Patients suffering of an atypical Parkinson syndrome\n\n          -  Psychiatric pathology\n\n          -  Tremor form (\u2265 3 (item tremor of UPDRS))\n\n          -  Patients with Impulsive control disorders\n\n          -  Depression, dementia\n\n          -  Pregnant\n\n          -  Under guardianship\n\n          -  In excluding period for another study\n\n          -  Any contra-indication to MRI\n\n        Healthy subject\n\n          -  Subject with neurological, psychiatric diseases\n\n          -  Depression, dementia\n\n          -  Pregnant\n\n          -  Under guardianship\n\n          -  In excluding period for another study\n\n          -  Any contra-indication to MRI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780467", 
            "org_study_id": "CHU-0139", 
            "secondary_id": "2012-002768-28"
        }, 
        "intervention": {
            "arm_group_label": [
                "patients  with and without treatment by L dopa)", 
                "healthy paired control"
            ], 
            "intervention_name": "Role of dopamine", 
            "intervention_type": "Behavioral"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dopamine", 
                "Dopamine Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Loss aversion", 
            "Dopamine", 
            "Parkinson's disease"
        ], 
        "lastchanged_date": "January 29, 2013", 
        "location": {
            "contact": {
                "email": "placarin@chu-clermontferrand.fr", 
                "last_name": "Patrick LACARIN", 
                "phone": "04 73 75 11 95"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont-Ferrand", 
                    "country": "France", 
                    "zip": "63003"
                }, 
                "name": "CHU Clermont-Ferrand"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.", 
        "overall_contact": {
            "email": "placarin@chu-clermontferrand.fr", 
            "last_name": "Patrick LACARIN", 
            "phone": "04 73 75 11 95"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Clermont-Ferrand", 
            "last_name": "Ulla MIGUEL", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "percentage of signal modification", 
            "safety_issue": "Yes", 
            "time_frame": "From day 1 (without L Dopa) to day 2 (with L Dopa)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780467"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cluster activation size", 
                "safety_issue": "Yes", 
                "time_frame": "from day 1 (without L Dopa) to day 2 (with LDopa)"
            }, 
            {
                "measure": "Brain activity indicators", 
                "safety_issue": "Yes", 
                "time_frame": "from day 1 (without L Dopa) to day 2 (with L Dopa)"
            }
        ], 
        "source": "University Hospital, Clermont-Ferrand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Clermont-Ferrand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}